KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inovio Pharmaceuticals (INO) Accumulated Expenses (2016 - 2026)

Inovio Pharmaceuticals' Accumulated Expenses history spans 16 years, with the latest figure at $650680.0 for Q4 2025.

  • On a quarterly basis, Accumulated Expenses fell 67.82% to $650680.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $650680.0, a 67.82% decrease, with the full-year FY2025 number at $650680.0, down 67.82% from a year prior.
  • Accumulated Expenses hit $650680.0 in Q4 2025 for Inovio Pharmaceuticals, down from $955970.0 in the prior quarter.
  • Over the last five years, Accumulated Expenses for INO hit a ceiling of $13.6 million in Q3 2021 and a floor of $650680.0 in Q4 2025.
  • Historically, Accumulated Expenses has averaged $6.4 million across 5 years, with a median of $5.6 million in 2023.
  • Biggest five-year swings in Accumulated Expenses: surged 133.15% in 2021 and later tumbled 78.74% in 2025.
  • Tracing INO's Accumulated Expenses over 5 years: stood at $10.3 million in 2021, then grew by 2.59% to $10.6 million in 2022, then tumbled by 77.67% to $2.4 million in 2023, then dropped by 14.52% to $2.0 million in 2024, then crashed by 67.82% to $650680.0 in 2025.
  • Business Quant data shows Accumulated Expenses for INO at $650680.0 in Q4 2025, $955970.0 in Q3 2025, and $1.5 million in Q2 2025.